Skip to main content
AIDX
NASDAQ Industrial Applications And Services

Record Q2 Cancer Test Revenue and Debt Elimination Highlight 20/20 BioLabs' Quarter

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.55
Mkt Cap
$6.742M
52W Low
$0.401
52W High
$50
52W Position info
37% above low
Off High info
99% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

AIDX sits 37% above its 52-week low of $0.401 on light trading volume (0.3× avg).

Summary

Record Q2 2026 cancer test revenue of $0.7 million, up 47% year-over-year, was reported with gross margin expanding to 41.7%. The company eliminated all convertible note debt and ended the quarter with $4.5 million in cash.


Key Events · Earnings and Guidance · AIDX

  • Record Q2 Cancer Test Revenue

    OneTest revenue increased 47.1% to $0.7 million, representing 95.3% of total revenue, with gross margin expanding to 41.7% from 30.5%.

  • Convertible Debt Eliminated

    All principal and accrued interest under secured convertible promissory notes was exchanged for Series E preferred stock on April 10, 2026, eliminating all convertible note debt from the balance sheet.

  • Cash Position Strengthened

    Cash and cash equivalents totaled $4.5 million as of June 30, 2026, up from $1.0 million at year-end 2025, primarily from $6.0 million in Series E preferred financing.

  • Firefighter Screening Programs Expand

    State-funded programs in Vermont and Maryland are expected to generate over $1.0 million in revenue through end of 2026, with the company expecting to test more than 35,000 firefighters by year-end.


Analysis · AIDX · Industrial Applications And Services

The strongest quarter yet for multi-cancer early detection testing saw OneTest revenue climb 47% to $0.7 million, with gross margin expanding to 41.7%. All convertible note debt has been eliminated and cash strengthened to $4.5 million, reducing near-term financing risk. However, net loss widened to $1.5 million and the company remains reliant on Series E preferred financing, with a standstill agreement limiting near-term dilution from Streeterville.

At the time of this filing, AIDX was trading at $0.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.40 to $50.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AIDX - Latest Insights

AIDX
Aug 17, 2026, 8:31 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.570
Real-time Price: $0.5503 info
Change: -$0.0197 (-3%) info
Market Cap: $6.742M info
AIDX
Aug 14, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.557
Real-time Price: $0.5503 info
Change: -$0.0067 (-1%) info
Market Cap: $6.742M info
AIDX
Aug 05, 2026, 12:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4435
Real-time Price: $0.5503 info
Change: +$0.1068 (+24%) info
Market Cap: $6.742M info
AIDX
Jul 22, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5381
Real-time Price: $0.5503 info
Change: +$0.0122 (+2%) info
Market Cap: $6.742M info
AIDX
Jul 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.6098
Real-time Price: $0.5503 info
Change: -$0.0595 (-10%) info
Market Cap: $6.742M info